Taken together, our results indicate that agonistic CD40 mAb treatment of mice bearing B16-F10 melanoma is associated with increased IFN signaling in tumor endothelial cells, up-regulation of inflammatory pathways and increased expression of molecules associated with increased endothelial barrier function and immunosuppression such as TRAIL and IDO1. The gene discussed is TNFSF10; the disease is melanoma.